|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:activeIngredient
|
gptkb:paroxetine
|
|
gptkbp:affiliatedWith
|
selective serotonin reuptake inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
1992
|
|
gptkbp:ATCCode
|
N06AB05
|
|
gptkbp:availableOn
|
gptkb:tablet
oral suspension
extended-release tablet
|
|
gptkbp:brand
|
gptkb:Aropax
gptkb:Seroxat
Pexeva
|
|
gptkbp:chemicalFormula
|
C19H20FNO3
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:discoveredBy
|
gptkb:Ferrosan
|
|
gptkbp:drugInteraction
|
gptkb:tricyclic_antidepressants
gptkb:warfarin
gptkb:NSAIDs
antipsychotics
other SSRIs
|
|
gptkbp:eliminationHalfLife
|
21 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Paxil
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
GlaxoSmithKline
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2003
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:riskFactor
|
increased suicidal thoughts in young people
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
weight gain
sweating
insomnia
drowsiness
dry mouth
sexual dysfunction
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:obsessive-compulsive_disorder
gptkb:panic_disorder
gptkb:post-traumatic_stress_disorder
gptkb:social_anxiety_disorder
gptkb:major_depressive_disorder
premenstrual dysphoric disorder
|
|
gptkbp:bfsParent
|
gptkb:paroxetine
|
|
gptkbp:bfsLayer
|
6
|